Back to search
FDAFDA · Food and drugs·Recall number D-0077-2025

Cinacalcet Tablets, 30 mg, packaged in: a) 30-count HDPE bottle (NDC 65862-831-30); b) 500-count HDPE bottle (NDC 65862-831-05), Rx Only, Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India.

Published December 11, 2024 · Recall initiated: November 7, 2024

Summary

FDA records drug Class II recall D-0077-2025, published December 11, 2024 and initiated November 7, 2024. Recalling firm: Aurobindo Pharma USA Inc; Status: Ongoing; Reported quantity: 102576 bottles; Lot: Lot #: a) CFSA23001A, CFSA23002A, CFSA23003A, Exp 03/31/2025; CFSA23004A, Exp 07/31/2025; CFSA23005A, Exp 10/31/2025; b) P2300191, P2300192, P2300193, P2300194, Exp 12/31/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Aurobindo Pharma USA Inc
Distributor
USA Nationwide
Lot
Lot #: a) CFSA23001A, CFSA23002A, CFSA23003A, Exp 03/31/2025; CFSA23004A, Exp 07/31/2025; CFSA23005A, Exp 10/31/2025; b) P2300191, P2300192, P2300193, P2300194, Exp 12/31/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Cinacalcet Tablets, 30 mg, packaged in: a) 30-count HDPE bottle (NDC 65862-831-30); b) 500-count HDPE bottle (NDC 65862-831-05), Rx Only, Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India. recalled?

Yes. FDA published recall D-0077-2025 on December 11, 2024. Reported hazard: cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

What should I do if I have this product?

Voluntary: Firm initiated · Letter